Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.

Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM.

Radiother Oncol. 2010 Nov;97(2):352-9. doi: 10.1016/j.radonc.2010.08.019. Epub 2010 Oct 9.

PMID:
20934765
2.

[Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].

Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):33-7. Chinese.

PMID:
19538866
3.

The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma.

Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S, Udagawa Y.

Int J Gynecol Cancer. 2011 Nov;21(8):1479-85. doi: 10.1097/IGC.0b013e31822265e7.

PMID:
21720251
4.

ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.

De Castro G Jr, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH.

Oncol Rep. 2011 Mar;25(3):693-9. doi: 10.3892/or.2011.1133. Epub 2011 Jan 3.

PMID:
21206986
5.

Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.

Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, Nonomura N.

Clin Cancer Res. 2011 Apr 15;17(8):2561-9. doi: 10.1158/1078-0432.CCR-10-1963. Epub 2010 Dec 21.

6.

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K.

Br J Cancer. 2008 Feb 26;98(4):832-9. doi: 10.1038/sj.bjc.6604211. Epub 2008 Jan 29.

7.

Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.

Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, Li XQ.

Lung Cancer. 2010 Jul;69(1):116-22. doi: 10.1016/j.lungcan.2009.09.013. Epub 2009 Oct 28.

PMID:
19875192
8.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553
9.

ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.

Torii Y, Kato R, Minami Y, Hasegawa K, Fujii T, Udagawa Y.

Anticancer Res. 2014 Jan;34(1):107-15.

PMID:
24403450
10.
11.

ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus.

Brabender J, Vallböhmer D, Grimminger P, Hoffmann AC, Ling F, Lurje G, Bollschweiler E, Schneider PM, Hölscher AH, Metzger R.

J Gastrointest Surg. 2008 Nov;12(11):1815-21. doi: 10.1007/s11605-008-0668-7. Epub 2008 Sep 3.

PMID:
18769985
12.

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ.

J Clin Oncol. 2001 Dec 1;19(23):4298-304.

PMID:
11731512
13.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.

Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2008 Jul-Aug;18(4):702-10. Epub 2007 Oct 24.

PMID:
17961161
14.

Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.

Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):679-84. doi: 10.1016/j.ijrobp.2009.02.050. Epub 2009 May 21.

PMID:
19464815
15.

Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer.

Tepeli E, Caner V, Büyükpınarbaşılı N, Çetin GO, Düzcan F, Elmas L, Bağcı G.

Mol Biol Rep. 2012 Jan;39(1):335-41. doi: 10.1007/s11033-011-0743-0. Epub 2011 May 7.

PMID:
21553054
16.

High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.

Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM.

Clin Cancer Res. 2004 Jun 1;10(11):3794-9.

18.

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr.

Clin Cancer Res. 2005 Mar 15;11(6):2215-21.

19.

A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients.

Woelfelschneider A, Popanda O, Lilla C, Linseisen J, Mayer C, Celebi O, Debus J, Bartsch H, Chang-Claude J, Schmezer P.

Carcinogenesis. 2008 Sep;29(9):1758-64. doi: 10.1093/carcin/bgn067. Epub 2008 Mar 10.

20.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Olaussen KA, Mountzios G, Soria JC.

Curr Opin Pulm Med. 2007 Jul;13(4):284-9. Review.

PMID:
17534174
Items per page

Supplemental Content

Write to the Help Desk